Adolor Corporation Announces Management Appointments
January 14 2010 - 9:00AM
Business Wire
Adolor Corporation (NasdaqGM: ADLR) today announced the
following promotions:
Michael D. Adelman has been promoted to the position of Vice
President, Marketing and Sales. Mr. Adelman, 39, joined Adolor in
late 2008 as Senior Director, Marketing where he directed the
Company’s marketing activities for ENTEREG® (alvimopan). Prior to
joining Adolor, Mr. Adelman held positions of increasing
responsibility at AstraZeneca Pharmaceuticals, LP in Product
Marketing and Sales, including serving on the Marketing Strategy
Leadership Team.
David P. Geoghegan has been promoted to Vice President,
Manufacturing. Mr. Geoghegan will continue to report to George R.
Maurer, Senior Vice President, Manufacturing and Pharmaceutical
Technologies. Mr. Geoghegan, 44, joined Adolor in 2004 as Senior
Director, Manufacturing Process Quality where he has led the
quality control of Adolor’s commercial supply chain. For over 20
years, Mr. Geoghegan has held technical, quality and management
positions in the biopharmaceutical industry. Prior to joining
Adolor, he worked most recently at MedImmune, Inc. as Director, QA
Corporate Compliance.
Kevin Darryl White has been promoted to Vice President,
Regulatory Affairs. Mr. White, 52, joined Adolor in 2008 as Senior
Director, Regulatory Affairs where he managed the regulatory
strategy for the Company’s commercial product and development
programs. For 30 years, Mr. White has held positions of increasing
responsibilities in both the pharmaceutical industry and the U. S.
Food and Drug Administration. He most recently was at Palatin
Technologies as Director, Regulatory Affairs.
"We are fortunate to have an extremely talented leadership team
at Adolor and I am pleased to be able to appoint Mike, David and KD
to these management positions," said Michael R. Dougherty,
President and Chief Executive Officer. "Their collective dedication
and expertise will continue to drive our commercial operations and
pipeline development."
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing
in the discovery, development and commercialization of novel
prescription pain management products.
Adolor’s first approved product in the United States is ENTEREG®
(alvimopan), which is indicated to accelerate the time to upper and
lower gastrointestinal recovery following partial large or small
bowel resection surgery with primary anastomosis. ENTEREG is
available for short-term use in hospitals registered under the
E.A.S.E.™ Program. For more information on ENTEREG, including its
full prescribing information, visit www.ENTEREG.com. In
collaboration with GlaxoSmithKline (GSK), the Company launched
ENTEREG in mid-2008.
The Company’s research and development pipeline includes: two
novel delta opioid receptor agonists, currently in mid-stage
clinical development in collaboration with Pfizer Inc. for chronic
pain; two opioid receptor antagonists, ADL7445 and ADL5945,
entering clinical development for opioid bowel dysfunction (OBD);
and several opioid and non-opioid discovery programs.
For more information, visit www.adolor.com.
Forward-Looking Statements
This press release, and oral statements made with respect to
information contained in this release, may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements provide Adolor's
current expectations or forecasts of future events. These may
include statements regarding anticipated scientific progress on its
research programs; development of potential pharmaceutical
products; interpretation of clinical results; prospects for
regulatory approval; market prospects for ENTEREG; and other
statements regarding matters that are not historical facts. You may
identify some of these forward-looking statements by the use of
words in the statements such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" or other words and terms of
similar meaning or that otherwise express contingencies, goals,
targets or future development. These statements are based upon
management's current expectations and are subject to risks and
uncertainties, known and unknown, that could cause actual results
and developments to differ materially from those expressed or
implied in such statements due to general financial, economic,
regulatory and political conditions affecting the biotechnology and
pharmaceutical industries, as well as more specific risks and
uncertainties facing Adolor such as those set forth in its reports
on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission. Adolor urges you to carefully review and
consider the disclosures found in its filings which are available
at http://www.sec.gov and from Adolor at www.adolor.com. Given the
uncertainties affecting pharmaceutical companies such as Adolor,
any or all of these forward-looking statements may prove to be
incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Adolor undertakes no obligation to
publicly update or revise the statements made herein or the risk
factors that may relate thereto whether as a result of new
information, future events, or otherwise, except as may be required
by law.
This press release is available on the website
http://www.adolor.com.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jul 2023 to Jul 2024